tirzepatide fda approved weight loss confirms shortage is still over, gives compounders a grace period Tirzepatide Wins FDA Approval for

Care Wellness Center is your one stop shop for healthcare

Status and phase Conditions Treatments Study type Funder types Identifiers About This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease

Mutations and all plasmid constructs were confirmed by DNA sequencing before use

& Gassama-Diagne, A